ライフサイエンスコーパス: axillary lymph node

1 at the cellular level until they entered the axillary lymph node.

2 nel lymph node biopsy, and 10 had a positive axillary lymph node.

3 mapping, and only one patient had a positive axillary lymph node.

4 e morphological characteristic of metastatic axillary lymph node.

5 needle aspiration of a palpable, ipsilateral axillary lymph node.

6 ed between primary breast tumours and paired axillary lymph nodes.

7 y measuring time to peak signal intensity in axillary lymph nodes.

8 The margins are negative, as are all 11 axillary lymph nodes.

9 breast cancer who underwent US assessment of axillary lymph nodes.

10 in the spleen and in inguinal, brachial, and axillary lymph nodes.

11 o residual invasive cancer in the breast and axillary lymph nodes.

12 the regional spread of breast cancer to the axillary lymph nodes.

13 evidence of invasive tumor in the breast and axillary lymph nodes.

14 age breast cancer without involvement of the axillary lymph nodes.

15 idence of invasive disease in the breast and axillary lymph nodes.

16 imary breast cancer and at least 10 involved axillary lymph nodes.

17 of these patients had residual tumor within axillary lymph nodes.

18 ancer patients, independent of the status of axillary lymph nodes.

19 wall and/or the ipsilateral supraclavicular/axillary lymph nodes.

20 t cancer patients with four or more involved axillary lymph nodes.

21 umor cells are unlikely to be found in other axillary lymph nodes.

22 mographic screening (elsewhere) had negative axillary lymph nodes.

23 istologic characteristics of the rest of the axillary lymph nodes.

24 ly 3 cm on exam, and multiple palpable right axillary lymph nodes.

25 multiple conglomerated 1-2 cm level I and II axillary lymph nodes.

26 There was no evidence of enlarged axillary lymph nodes.

27 ologic complete response (pCR) in breast and axillary lymph nodes.

28 absence of invasive cancer in the breast and axillary lymph nodes.

29 even lesions in the neck, five (55%) of nine axillary lymph nodes, 11 (50%) of 22 bone metastases, an

30 < .001) and had a larger number of involved axillary lymph nodes (41% v 26% had > 3 involved nodes;

31 stology) as did other features (27% positive axillary lymph nodes, 63% positive estrogen receptors, a

32 Of women with positive axillary lymph nodes, 83% aged less than 51 years and 52

33 f 20 primary breast tumors and their matched axillary lymph nodes, a high concordance (Fisher's exact

34 er concentration of RPV was delivered to the axillary lymph nodes (AL) (C(max) 2466 ng/g - T(max) 3 d

35 accurate exclusion of clinically significant axillary lymph node (ALN) disease.

36 tients achieving pCR of cytologically proven axillary lymph node (ALN) metastases.

37 ession in primary breast cancers can predict axillary lymph node (ALN) metastasis, we assessed differ

38 Pathologic axillary lymph node (ALN) status is an important prognos

39 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

40 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

41 iption polymerase chain reaction (RT-PCR) in axillary lymph nodes (ALN) of breast cancer patients.

42 therapy in patients with 10 or more positive axillary lymph nodes (ALN) to reduce the high loco-regio

43 Axillary lymph nodes (ALNs) are the regions where BC cel

44 A was prominently expressed in the liver and axillary lymph nodes, although preliminary data suggest

45 bsence of invasive disease in the breast and axillary lymph nodes, analysed by intention to treat.

46 -10-fold in primary tumor volumes; and in an axillary lymph node and lung metastasis as compared with

47 all survival based on the number of positive axillary lymph nodes and (in N0 patients) pathologic tum

48 perable breast cancer involving four or more axillary lymph nodes and had completed mastectomy or bre

49 enrolled with between one and three positive axillary lymph nodes and Ki-67 of at least 20% as an add

50 icant incidence of metastatic disease to the axillary lymph nodes and may benefit most from selective

51 h biopsy-proved metastatic adenocarcinoma to axillary lymph nodes and occult primary tumor underwent

52 tion is that patients who develop disease in axillary lymph nodes and subsequently undergo ALND have

53 primary breast tumours to that in metastatic axillary lymph nodes and to determine the correlation be

54 ed significantly with the number of positive axillary lymph nodes and with postchemotherapy c-erbB-2

55 iltrating lobular carcinoma in the breast or axillary lymph nodes) and 12-month follow-up.

56 nd intraductal disease in the breast and the axillary lymph nodes), and the safety of adding bevacizu

57 tution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype

58 T excels in detecting primary breast masses, axillary lymph nodes, and distant metastases; can comple

59 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes on e

60 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes.

61 etween radiotracer uptake in spleen, tonsil, axillary lymph nodes, and peripheral blood CD4 T-cell co

62 n of lymph node status by number of involved axillary lymph nodes; and new classifications for metast

63 gn transport of breast epithelial cells into axillary lymph nodes are recently described phenomena.

64 Our group has shown that nonsentinel axillary lymph nodes are unlikely to contain tumor cells

65 ith combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR, decreased from

66 ne of five Ontario study centers followed by axillary lymph node assessment (ALNA) consisting of sent

67 tients diagnosed with at least four positive axillary lymph nodes at diagnosis who underwent anthracy

68 in women who had more than three metastatic axillary lymph nodes at the time of diagnosis.

69 g NHPs had significant (18)FDG uptake in the axillary lymph nodes at the time of MPXV challenge with

70 mance of breast MRI in diagnosing metastatic axillary lymph nodes based on the pathological result.

71 and high NPV (96.4%) in detecting metastatic axillary lymph nodes, but its specificity was only fair

72 elevated D-dimer (> 100 ng/mL) and involved axillary lymph nodes (chi(2) test; P =.001).

73 excision of the tumour (1 cm margin) and an axillary lymph-node clearance or sample, all patients re

74 ion took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-r

75 ns of macrophages isolated from the spleens, axillary lymph nodes, colons, jejuna, and livers of heal

76 Two of the 11 axillary lymph nodes contained metastatic carcinoma.

77 P < .001), high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more sev

78 cer diagnosis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt

79 relative risk, 0.83 [CI, 0.77 to 0.90]) and axillary lymph node dissection (adjusted relative risk,

80 n with breast cancer, the role of completion axillary lymph node dissection (ALND) after identificati

81 l lymph node biopsy (SLNB) alone, SLNB+RLNR, axillary lymph node dissection (ALND) alone, and ALND+RL

82 Axillary lymph node dissection (ALND) as part of surgica

83 SLNB has replaced axillary lymph node dissection (ALND) as the staging mod

84 staging information with less morbidity than axillary lymph node dissection (ALND) for patients with

85 node biopsy (SLNB) was developed to replace axillary lymph node dissection (ALND) for staging early

86 Axillary lymph node dissection (ALND) has been a part of

87 Axillary lymph node dissection (ALND) has been a standar

88 lymph nodes (SLNs) were negative, SLNB with axillary lymph node dissection (ALND) if SLNB or PET was

89 For breast cancer patients, the role of the axillary lymph node dissection (ALND) in the management

90 Recent enthusiasm for limiting axillary lymph node dissection (ALND) in women with brea

91 l lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to

92 ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in

93 n both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of

94 itivity for macrometastasis (Ma), leading to axillary lymph node dissection (ALND) only when strictly

95 hat consisted of either total mastectomy and axillary lymph node dissection (ALND) or segmental maste

96 inel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph

97 In all cases with a tumor-involved SN, axillary lymph node dissection (ALND) was recommended.

98 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

99 LE is a serious complication of axillary lymph node dissection (ALND) with an incidence

100 ve been proposed to replace the conventional axillary lymph node dissection (ALND) with its concomita

101 e predicted that 20 to 30 cases of SLND with axillary lymph node dissection (ALND) would enable surge

102 trolled trial in which SNB was compared with axillary lymph node dissection (ALND), four limited meta

103 orized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

104 with a positive SLN who underwent completion axillary lymph node dissection (ALND).

105 mph nodes (SLNs) who did and did not undergo axillary lymph node dissection (ALND).

106 lymphedema (BCRL) in patients who underwent axillary lymph node dissection (ALND).

107 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

108 performed with or without SLNB, TLNB, and/or axillary lymph node dissection (ALND).

109 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

110 e categorized in 4 groups: SLN-negative with axillary lymph node dissection (ALND; n = 326), SLN-nega

111 ph nodes (SLNs) generally undergo completion axillary lymph node dissection (cALND), either concurren

112 the breast and regional nodes after BCS and axillary lymph node dissection (Group 1) were compared t

113 included body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymp

114 Axillary lymph node dissection (P < 0.0001), higher body

115 SLN biopsy (SLNB) alone or SLNB followed by axillary lymph node dissection (SLNB/ALND) between June

116 opsy (SLNB) alone and after SLNB followed by axillary lymph node dissection (SLNB/ALND).

117 results (sentinel lymph node biopsy [SNB] or axillary lymph node dissection [ALND]) were compared wit

118 2 patients were randomly assigned to receive axillary lymph node dissection and 2404 to receive axill

119 inel node, 744 had been randomly assigned to axillary lymph node dissection and 681 to axillary radio

120 Axillary lymph node dissection and axillary radiotherapy

121 Breast-conserving surgery combined with axillary lymph node dissection and radiotherapy or maste

122 d the localized lymph node before completion axillary lymph node dissection and used radiography of t

123 For selected patients, axillary lymph node dissection appears to have little in

124 er were significantly less likely to receive axillary lymph node dissection as determined by logistic

125 Axillary lymph node dissection can identify the presence

126 lar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior

127 me progressively less extensive, with formal axillary lymph node dissection confined to a dwindling g

128 Axillary lymph node dissection continues to be routinely

129 y useful for intraoperative or postoperative axillary lymph node dissection decisions.

130 ence occurred in four of 744 patients in the axillary lymph node dissection group and seven of 681 in

131 In the axillary lymph node dissection group, 220 (33%) of 672 p

132 l lymph node biopsy group and 7 (37%) in the axillary lymph node dissection group.

133 py group compared with an expected 2% in the axillary lymph node dissection group.

134 oup, 220 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive n

135 ymph nodes (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (

136 east cancers while avoiding the morbidity of axillary lymph node dissection if the nodes do not conta

137 gest that it is time to reassess the role of axillary lymph node dissection in patients who undergo c

138 Indications for omission of completion axillary lymph node dissection in patients with two or f

139 These findings do not support routine use of axillary lymph node dissection in this patient populatio

140 Of the 59 patients, 48 had axillary lymph node dissection irrespective of the resul

141 Complete axillary lymph node dissection is indicated in patients

142 st cancer who have a positive sentinel node, axillary lymph node dissection is the present standard.

143 This suggests that axillary lymph node dissection may not be necessary in p

144 erated allocation schedule to receive either axillary lymph node dissection or axillary radiotherapy

145 Although axillary lymph node dissection provides excellent region

146 arm was noted significantly more often after axillary lymph node dissection than after axillary radio

147 SLN biopsy followed by completion level I/II axillary lymph node dissection to determine the false-ne

148 ecurrence was 0.43% (95% CI 0.00-0.92) after axillary lymph node dissection versus 1.19% (0.31-2.08)

149 A complementary axillary lymph node dissection was performed in all pati

150 patients undergoing total mastectomy and/or axillary lymph node dissection were randomized to standa

151 the ability to achieve the results of total axillary lymph node dissection without the risks of surg

152 of node-positive patients and of completion axillary lymph node dissection) were analyzed to rule ou

153 bility to obtain prognostic information (ie, axillary lymph node dissection), tends to minimize treat

154 e, approximately 10% of women do not have an axillary lymph node dissection, 11% to 26% do not have t

155 .4% underwent an initial SLNB, 37.2% initial axillary lymph node dissection, and 6.3% no axillary sur

156 eoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate

157 andard primary tumor therapy, to not receive axillary lymph node dissection, and to not receive radia

158 We have previously found that axillary lymph node dissection, both clinically and in a

159 Two patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for

160 y, followed by breast-conserving surgery and axillary lymph node dissection, which revealed residual

161 rm morbidity and better quality of life than axillary lymph node dissection.

162 authors examined receipt of radiotherapy and axillary lymph node dissection.

163 All patients were offered axillary lymph node dissection.

164 ents in the initial group went on to undergo axillary lymph node dissection.

165 the unnecessary complications of a complete axillary lymph node dissection.

166 ents would have been spared the morbidity of axillary lymph node dissection.

167 persistent poverty underwent mastectomy and axillary lymph node dissection.

168 r to overall survival for those treated with axillary lymph node dissection.

169 s of any size continue to mandate completion axillary lymph node dissection.

170 is an accurate, less invasive alternative to axillary lymph node dissection.

171 of NAC, all patients had breast surgery with axillary lymph node dissection.

172 either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection.

173 ocal recurrence rate and similar survival to axillary lymph node dissection.Preoperative axillary ult

174 y, because a separate incision is needed for axillary lymph-node dissection, and postoperative radiot

175 The goals of axillary-lymph-node dissection (ALND) are to maximise su

176 rgery but still offer outcomes equivalent to axillary-lymph-node dissection (ALND).

177 sentinel-lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replace

178 The previously undisputed gold standard of axillary-lymph-node dissection for staging has now been

179 on the present role and routine practice of axillary-lymph-node dissection in early breast cancer, t

180 h-node biopsy, but also lymph-node sampling, axillary-lymph-node dissection, and observation alone.

181 s practice pattern could lead to unnecessary axillary lymph node dissections and lymphedema.

182 e, 36-79 years) with breast cancer before 52 axillary lymph node dissections.

183 Despite guidelines recommending against axillary lymph node evaluation in women with DCIS underg

184 Although axillary lymph node evaluation is standard of care in th

185 Axillary lymph node examination revealed residual tumor

186 Invasive cancers that had spread to axillary lymph nodes exhibited higher SF content than di

187 strated equally well in benign and malignant axillary lymph nodes for all three groups.

188 strated that SLN biopsy can be used to stage axillary lymph nodes for breast cancer.

189 (US)-guided fine-needle aspiration (FNA) of axillary lymph nodes for preoperative staging of breast

190 ty of catecholaminergic neural fibers within axillary lymph nodes from adult rhesus macaques.

191 ns of the HEVs are also characterized in the axillary lymph nodes from human breast cancer patients w

192 Two hundred and twenty-seven axillary lymph nodes from preoperative breast MRIs were

193 ize averaged 5.7 cm with clinically positive axillary lymph nodes in 23 patients (57%).

194 The MDA-MB-231 cells metastasized to axillary lymph nodes in a SCID mouse model.

195 lymph nodes metastasis and the diagnosis of axillary lymph nodes in patients with breast cancer is i

196 US-guided FNA of axillary lymph nodes in patients with newly diagnosed br

197 on in both peripheral blood and the draining axillary lymph node, indicating significant BCG vaccine-

198 y breast tumors resulted in viral transit to axillary lymph nodes, infection of lymphatic metastases,

199 Patients and physicians should tailor axillary lymph node interventions to maximize regional d

200 rder interactions were considered: number of axillary lymph nodes involved (zero v one to three v fou

201 years or older without prior chemotherapy or axillary lymph node involvement and (2) the hypofraction

202 Axillary lymph node involvement in breast cancer is a ma

203 , age, comorbid disease, prior chemotherapy, axillary lymph node involvement, intensity-modulated rad

204 and micrometastasis to the SLN had remaining axillary lymph node involvement.

205 50 years or those with prior chemotherapy or axillary lymph node involvement.

206 munohistochemical examination of ipsilateral axillary lymph nodes is a reliable, prognostically valua

207 Reliable pathologic stage classification of axillary lymph nodes is an important determinant of prog

208 rimary breast cancer and 10 or more involved axillary lymph nodes is poor.

209 d cervical lymph nodes but fewer than 20% of axillary lymph nodes, livers, brown fat samples, kidneys

210 group included 17 patients with ipsilateral axillary lymph node (LN) metastases.

211 went clip insertion into the most suspicious axillary lymph node (LN) were eligible.

212 of 2.68 +/- 1.0 mm between FMT and SPECT for axillary lymph node localization.

213 Axillary lymph nodes marked with a clip can be localized

214 had a breast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

215 189 consecutive invasive IBCs (53 with axillary lymph node metastases and 136 without) were stu

216 Axillary lymph node metastases are most significantly re

217 in the breast is correlated with absence of axillary lymph node metastases at final pathology (ypN0)

218 There were axillary lymph node metastases in four samples (9%).

219 Patients with axillary lymph node metastases may benefit from postmast

220 h negative PET scans had such a low risk for axillary lymph node metastases that axillary dissection

221 The rate of axillary lymph node metastases was consistent with SLN t

222 Axillary lymph node metastases were more frequent and ha

223 d with a 1% to 3% reduction in recurrence of axillary lymph node metastases, but is associated with a

224 the 181 patients with lymphatic invasion had axillary lymph node metastases, compared with 19% of the

225 ive breast carcinomas and is associated with axillary lymph node metastases.

226 hy, and can also make it difficult to detect axillary lymph node metastases.

227 as inversely correlated with the presence of axillary lymph node metastases.

228 tify variables independently associated with axillary lymph node metastases.

229 imary human breast carcinomas and associated axillary lymph node metastases.

230 serve as a cost-effective screening test for axillary lymph node metastases.

231 -1 ratio was observed in primary tumors with axillary lymph node metastasis than in node-negative tum

232 y into nude mice, the primary tumor volumes, axillary lymph node metastasis, and lung metastasis were

233 coefficient (ADC) value in the detection of axillary lymph node metastasis.

234 nfiltrating ductal carcinomas; and one (2%), axillary lymph node metastasis.

235 primary tumor subclones, or subclones in an axillary lymph node metastasis.

236 t to substitute it for SLNB for exclusion of axillary lymph node metastasis.

237 It is difficult to accurately assess axillary lymph nodes metastasis and the diagnosis of axi

238 ease recurrence in a cohort of patients with axillary lymph node-negative breast cancer.

239 ion of chromosome 14q 31.2 is much higher in axillary lymph node-negative primary breast tumors than

240 d ratio of 0.342 (95% CI, 0.17 to 0.69), and axillary lymph node-negative status yielded a hazard rat

241 uding internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole

242 ot sufficiently sensitive to detect positive axillary lymph nodes, nor is it sufficiently specific to

243 LNs removed, no cancer was identified in the axillary lymph nodes of 215 patients, yielding a patholo

244 to those in spleen, IL-10-positive cells in axillary lymph nodes of coinfected animals were predomin

245 capacity to completely clear the breast and axillary lymph nodes of invasive tumor before surgery.

246 to stimulate CD4(+) T cells derived from the axillary lymph nodes of mice vaccinated with irradiated

247 Methylene blue dye accumulation in axillary lymph nodes of seven healthy Sprague-Dawley rat

248 ne mastectomy and had at least four positive axillary lymph nodes or primary tumour stage T3-4 diseas

249 s, primary tumors and contralateral positive axillary lymph nodes, or two ipsilateral tumors).

250 rative activity in a cohort of patients with axillary lymph node-positive breast cancer and compare t

251 identification of a subset of patients with axillary lymph node-positive breast cancer with an impro

252 We enrolled 4950 women with axillary lymph node-positive or high-risk, lymph node-ne

253 A subset of axillary lymph node-positive patients with improved prog

254 node-negative primary breast tumors than in axillary lymph node-positive primary breast tumors.

255 Premenopausal women with axillary lymph node-positive, steroid hormone receptor-p

256 Injection of recombinant SLC in the axillary lymph node region led to a marked reduction in

257 IA) during transport from the forepaw to the axillary lymph node region of a rat.

258 for drainage into the cervical, inguinal, or axillary lymph nodes, respectively.

259 tumor response was predictive of a complete axillary lymph node response (P<.01 ).

260 ll carcinoma and breast cancer metastases to axillary lymph nodes resulted in areas under the curve a

261 otal, 47 paired breast tumour and metastatic axillary lymph node samples were collected in this study

262 The existing standard for axillary lymph node staging in breast cancer patients wi

263 or accurate, noninvasive imaging of SLNs for axillary lymph node staging in breast cancer patients.

264 SLN biopsy is a new standard of care for axillary lymph node staging in breast cancer.

265 When performed, pathologic axillary lymph node staging was node-negative (n=86).

266 Axillary lymph node status is the most important factor

267 Axillary lymph node status is the single most important

268 However, tumor size and axillary lymph node status were clearly superior prognos

269 In contrast, histology and axillary lymph node status were significant predictors o

270 growth factor receptor 2 (HER2) status; and axillary lymph node status with chi(2) or Fisher exact t

271 o age, stage, tumor site, tumor size, grade, axillary lymph node status, extent of surgery, and radio

272 r site, tumor size, grade, ER and PR status, axillary lymph node status, extent of surgery, and RT, t

273 s were analyzed in relation to the patients' axillary lymph node status, menopausal status, disease s

274 Axillary lymph node status, site of relapse, and hormone

275 stic parameter independent of tumor size and axillary lymph node status.

276 ias was not observed in the non-gut-draining axillary lymph nodes, suggesting that the Th17 bias was

277 cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adj

278 tion system (balanced for number of involved axillary lymph nodes, tumour stage, oestrogen receptor s

279 nomas, and metastatic breast carcinomas from axillary lymph nodes using quantitative TaqMan reverse t

280 A tumor-positive axillary lymph node was marked with a I seed in 100 pati

281 While the mean ADC value of malignant axillary lymph nodes was 0.749 10(-3) mm(2)/s (0.48-1.34

282 imination power between benign and malignant axillary lymph nodes was as follows: sensitivity - 60%;

283 US-guided 14-gauge CNB of abnormal axillary lymph nodes was performed in 100 of 144 patient

284 Axillary lymph nodes were analyzed using an in vivo fluo

285 Axillary lymph nodes were classified at ultrasound exami

286 ases in primary breast-cancer patients whose axillary lymph nodes were classified, by conventional me

287 for breast cancer confined to the breast and axillary lymph nodes were entered in a prospective study

288 Lymphadenopathy and immune activation in the axillary lymph nodes were evident in IV- and IB-infected

289 Primary tumors and involved axillary lymph nodes were identified, and the [(18)F]-FD

290 Prior to NST, proven tumor-positive axillary lymph nodes were marked with a I seed.

291 ongly with disease-specific survival whether axillary lymph nodes were negative or positive for metas

292 , or IIIA breast cancer involving 10 or more axillary lymph nodes were randomized after surgery and s

293 ng mammography, asymmetrically enlarged left axillary lymph nodes were seen in a healthy 70-year-old

294 st cancer involving four or more ipsilateral axillary lymph nodes were treated with nine cycles of ch

295 The MARI procedure [marking the axillary lymph node with radioactive iodine (I) seeds] i

296 s sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI),

297 Axillary lymph nodes with abnormal US findings can be sa

298 an occult metastatic melanoma involving the axillary lymph nodes with an unknown primary site.

299 immune response in primary tumors and in the axillary lymph nodes with metastasis (ALN(+)) in breast

300 immune cells in the primary tumor and in the axillary lymph nodes without metastasis (ALN(-)) differe